Trial Profile
A Randomized Controlled Multicentered Phase 2/3 Study to Evaluate SHR-1210 (PD-1 Antibody) in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Failed or Intolerable to Prior Systemic Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 14 Mar 2024 Status changed from active, no longer recruiting to completed.
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress